The insider selling is trivial in size and likely reflects post-earnings window opening and tax planning. The concurrent $500M ATM offering introduces potential dilution overhang, but the $500M buyback authorization partially offsets this. Monitor the pace of ATM usage and any insider purchases as a signal of management conviction.
BBIO drugs
BBIO drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 20 $68.22entry
- T+1 · 6mo ago +3.02%α +2.83% · $70.28
- T+5 · 6mo ago +0.34%α −1.47% · $68.45
- T+20 · 5mo ago −2.86%α −3.60% · $66.27
- T+60 · 3mo ago +17.06%α +12.06% · $79.86
Price Chart
How similar events traded
Executive Summary
A cluster of insider selling at BridgeBio Pharma (BBIO) occurred in the week following the Q1 2026 earnings release and the filing of a $500M at-the-market (ATM) equity offering. CFO Thomas Trimarchi sold $678K in open-market shares, and Director Randal Scott sold $413K, while CEO Neil Kumar exercised options and surrendered shares for tax withholding. The total open-market sales of $1.09M represent ~0.009% of BBIO's $12.8B market cap, which is trivial. The cluster is likely driven by routine post-earnings blackout window opening and tax-related transactions, not a coordinated bearish signal.
Key Financial Metrics
Key Facts
- CFO Thomas Trimarchi sold 10,456 shares for $678K on May 18, 2026.
- Director Randal Scott sold 6,200 shares for $413K on May 15, 2026.
- CEO Neil Kumar exercised 33,544 options (non-cash) and surrendered 36,236 shares for tax withholding ($2.4M).
- Total open-market selling of $1.09M is only 0.009% of BBIO's $12.8B market cap.
- Q1 2026 revenue was $194.5M, including $180.6M in Attruby net product revenue.
- Company filed a $500M ATM equity offering on May 7, 2026, concurrent with a $500M share buyback authorization.
- Cash and marketable securities stood at $940.2M as of March 31, 2026.
Financial Impact
Open-market insider sales total $1.09M, which is immaterial relative to BBIO's $12.8B market cap.
Risk Factors
- The $500M ATM equity offering could dilute existing shareholders if fully utilized.
- Insider selling, while small, may continue if the stock appreciates further.
- Pipeline execution risk for BBP-418, encaleret, and infigratinib NDAs.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-BBIO-1779222659731 |
Track record
38 reports on BBIO
10 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 14 of 15 went positive at some point.
Filters
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 Now $77.36 −1.04% settles Dec 11
- Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $77.36 −0.73% settles Dec 8
- Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 Now $77.36 −0.73% settles Dec 8
- Oct 29, 202618d ago 8-K Bullish 6/10 No price data
- Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $77.36 +3.22% settles Nov 30
- Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $77.36 +9.23% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $77.36 +13.56% settles Nov 19
- Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $77.36 +22.21% ▲ +24.28% +27.89% vs SPY
- Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $77.36 +15.53% ▲ +10.56% +13.73% vs SPY
- Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $77.36 +15.53% ▲ +10.56% +13.73% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers